FASN and prostate carcinoma: To evaluate the ability of alternative FASN inhibitors to sensitize prostate cancer cells to radiation, clonogenic assays were carried out on PC3 cells 24 hours after simultaneous administration of x-rays and TVB-3166 (Fig 2C) or Orlistat (Fig 2D).